Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Move Headquarters Down the Road

Premium

This story was originally published Jan. 10.

Illumina plans to move its headquarters to a new site in San Diego, according to a filing with the Securities and Exchange Commission last week.

Under the terms of the lease, signed on Dec. 30, Illumina's headquarters will move from its current location just east of the University of California San Diego campus to a larger facility at 5200 Research Place, less than two miles south.

The new site initially consists of two office buildings and a central plant building, totaling about 350,000 square feet. A third office building with 123,000 square feet has yet to be built. In addition, Illumina has the right to further expand and to lease one or more of three additional office buildings that may be built. It also has a right of first refusal regarding sales of the facility to others.

The proposed start date of the 20-year lease is Nov. 1, and Illumina has four five-year options to extend the lease, as well as a one-time option to terminate the lease after 15 years.

The company will pay approximately $335.1 million in rent during the initial term of the lease, not including any expansion buildings.

According to the company's 2009 annual report, as of Jan. 3, 2010 the company was leasing 272,000 square feet of space in San Diego for R&D, manufacturing, storage, distribution, and administrative purchases.

The company also leases 105,000 square feet in Hayward, Calif.; 49,000 square feet in Little Chesterford, UK; 36,000 square feet in Singapore; 11,500 square feet in the Netherlands; 6,500 square feet in Tokyo; 4,000 square feet in Melbourne, Australia; and 3,000 square feet in China.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more